Background. Hepatitis C virus (HCV) is an important cause of chronic hepatitis resulting in end stage liver disease and hepatocellular carcinoma. Direct acting antivirals (DAAs) interfere with the HCV lifecycle and result in high rates of sustained virologic response (SVR). We hypothesized that treatment with DAAs in a real world setting is as successful in HCV/HIV coinfected patients as it is in HCV monoinfected patients, and that some degree of fibrosis regression can be observed after completion of therapy in both groups.
Methods. We retrospectively reviewed data from patients who received treatment for HCV from 2014 to 2016 at the Infectious Diseases clinic and collected demographic characteristics, HCV genotype and viral load, DAA regimen, SVR rates, and whether or not fibrosis improved at 12 or 24 weeks after treatment completion defined as one METAVIR stage improvement in FibroSURE™ score to estimate fibrosis. In those with HIV, HIV viral load, CD4 count and HIV antiretroviral regimen were examined.
Results. Out of 41 patients in each group, 24 had completed therapy in the monoinfected group and 26 in the coinfected group. In the monoinfected group, 22 (92%) achieved SVR. In the coinfected group, 26 (100%) achieved SVR. The SVR rates of the monoinfected group and coinfected group did not differ significantly (P = .956). In the monoinfected group, 10/17 (59%) had an improvement in FibroSURE™ score, and 7/17 (41%) had no change. In the coinfected group, 2/9 (22.2%) patients demonstrated an improvement in FibroSURE™ score, 4/9 (44.4%) had no change, and 3/9 (33%) had an increase in FibroSURE™ score. There was no significant difference in the change in FibroSURE™ score before and after SVR between the two groups (P = .100).
Conclusion. In this small study, although not statistically significant, coinfected patients treated with DAAs had higher SVR rates than monoinfected patients. Treatment failure in the monoinfected group was linked to nonadherence, whereas, success of the coinfected patients was likely related to engagement in routine HIV care. Although not statistically significant, there were more patients in the monoinfected group that had an improvement in FibroSURE™ score, however the small sample size precludes any definitive conclusions. Methods. We reviewed data of patients with HCV/HIV co-infections treated with ledipasvir/sofosbuvir and post EOT viremia. Viral load was detected using Roche Second-Generation Cobas AmpliPrep/Cobas TaqMan which has high sensitivity and specificity with no reported cross-reactivity.
Results. Over the course of two years, we treated a total of 112 HCV/HIV co-infected patients. Four patients had EOT viremia (3.5%). During post-EOT HCV VL monitoring single episodes of HCV viremia (157-4511 IU/mL) were detected at 4-14 weeks post-EOT. All occurrences were preceded and followed by at least one undetectable HCV VL.
All patients reported excellent adherence to HCV therapy (pill count and patient report) except for one patient who missed two weeks of therapy. All patients had absolute CD4+ cell count >250 cells/mm3. Saturday, October 7, 2017: 12:30 PM Background. HCV/HIV co-infected patients have a higher risk of liver disease progression and mortality despite highly effective ART. Near 100% cure rate for HCV infection can be achieved by current direct-acting agents (DAA) against HCV. Therefore, treatment for all patients with HCV/HIV has been recommended by IDSA/ AASLD.
Setting: PHC is a Ryan White Care Act funded HIV outpatient clinic providing care for approximately 900 patients in Pittsburgh, PA.
Methods. At our clinic, a quality improvement project incorporating treatment algorithms targeting HCV/HIV was established for providers to guide HCV therapy.
Results. From January 1, 2014 to April 30, 2017, a total of 71 (12 F 59 M; 35 AA/1 H/35 W; Risk: 38 IVDU/31 MSM) HCV/HIV co-infections were identified (GT1: 57; GT3: 6; GT4: 1) with median age of 52 years (range: 21-73). Among them, 21 had fibrosure scores ≥ 3 and 22 <2. Out of 43 patients, 38 completed DAA (test of cure: 34) and 5 are currently on therapy. Lengths of treatment were 8 weeks (4), 12 weeks (30), 16 weeks (1) and 24 weeks (3). All patients had undetectable HCV viral loads at end of treatment (EOT) and test of cure (TOC) visits. Owing to our clinic staff members' persistent efforts, 5 patients remained adherent to therapy despite having medical events requiring inpatient admission. One patient skipped 7 days of therapy (D22-D28) but still achieved undetectable levels at the EOT and TOC.
Among those who had not received DAA (28), 5 died (AIDS:1, Malignancy:2, ESRD:2, Liver disease:1), 3 patients cleared the HCV virus without DAA; 4 Incarcerated; and 3 lost to care. Other barriers to therapy included Fibrosure <2 (preceding 2/1/2017), metastatic cancer, noncompliance and neuropsychiatric illness.
Conclusion. With DAAs, HCV co-infection rate at our PHC has decreased from 8% to 1.5%, anticipating further decrease to 0.5%. In our cohort, there were four HCV/HIV with GT1a were successfully treated with 8 weeks' course. This is not currently endorsed by the IDSA/AASLD guidelines for the co-infected population, however. Appropriate DAA HCV/HIV therapy coupled with intensive counseling and monitoring can possibly achieve 100% cure rate and elimination of HCV infection in HIV. 
